Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
D1.372 - Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG
D1.374 - Genetic susceptibility to radiocontrast media-induced anaphylaxis: A microarray gene chip study in a Korean population
D1.365 - Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms
D1.366 - “Intense peri-vaginal itching as a lone symptom”: a unique presentation of Progesterone (Progestogen) hypersensitivity (PH)
D1.367 - Risk factors for immediate hypersensitivity reactions to rituximab
D1.369 - Immediate hypersensitivity to dostarlimab successfully managed with desensitization
D1.370 - Desensitisation to low-dose acetylsalicylic acid in NERD. Clinical follow-up of aspirin therapy after desensitisation (ATAD)
D1.371 - Nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema: antioxidant enzymes activities and associated genetic variants
D1.373 - Hypersensitivity to Biologic Therapies: Mechanism of Cross-reactivity
D1.375 - Retrospective Analysis of Perioperative Hypersensitivity Reactions: Single-Center Experience
D1.376 - Successful Desensitization with Temozolomide in a Patient with a Hypersensitivity Reaction to Temozolomide
D1.377 - Folic Acid Allergy: A Rare Case
D1.378 - Hypersensitivity During Continuous 5-Fluorouracil Infusion: Two Cases Successfully Managed With Desensitization
D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
D3.158 - Dupilumab Response in a Patient with Severe Asthma Refractory to Anti-IL5 Therapy: A Case Report
D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor
D3.153 - Add-on Dupilumab therapy significantly reduces severe asthma exacerbations and emergency visits in patients with severe persistent asthma requiring oral corticosteroids for maintenance therapy: our experience in Réunion Island
D3.154 - Trends in Bronchial Asthma Incidence in Crimea: Analysis from 2017-2024 with Age-Specific Insights
D3.155 - Th2–Th17 immune shift following dupilumab therapy
D3.156 - Pulmonary embolism in a young asthma patient
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download